DiabetologyNews.net

Diabetology Xagena

Recent guidelines governing anti-diabetic medications increasingly advocate Metformin as first-line therapy in all patients with type 2 diabetes. However, Metformin could be associated with increased ...


New analyses have shown risk reductions were consistent across age groups for cardiovascular outcomes, including cardiovascular death, with Empagliflozin ( Jardiance ) compared with placebo when added ...


New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in people with type 2 diabetes with establis ...


The FDA ( Food and Drug Administration ) has required labeling changes regarding the recommendations for Metformin-containing medicines for diabetes to expand Metformin’s use in certain patients with ...


The FDA ( Food and Drug Administration ) has found that type 2 diabetes medicines containing Saxagliptin and Alogliptin may increase the risk of heart failure, particularly in patients who already hav ...


New data from a clinical trial led by cardiologists at Brigham and Women's Hospital ( BWH ) and the Duke Clinical Research Institute indicates that the non-statin, cholesterol-lowering drug Ezetimibe ...


The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The trial investigated the efficacy and safety of 0.5 mg and 1.0 m ...


Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug Sitagliptin ( Januvia ) without an increased risk of cardiovascular complications, even if they have ...


Positive top-line results from EMPA-REG OUTCOME were announced. This is a long-term clinical trial investigating cardiovascular ( CV ) outcomes for Jardiance ( Empagliflozin ) in more than 7,000 adult ...


The aim of a study was to identify risk factors for the development of statin-associated diabetes mellitus ( DM ). The study was conducted in two phases. Phase one involved high-throughput in silic ...


In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes ( T1D ), led by UC San Francisco researchers and physicians, patients experienced no serious adverse reactions after r ...


Reliable quantification of the association between blood pressure and risk of type 2 diabetes mellitus is lacking. A study sought to determine the association between usual blood pressure and risk of ...


Empagliflozin ( Jardiance ) has significantly reduced the risk of the combined endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 14% when added to standard of ca ...


Omarigliptin, an investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, has achieved its primary efficacy endpoint in a phase 3 study. Omarigliptin was found to be ...


Oral glucose-lowering medications are associated with excess risk of heart failure ( HF ). Given the absence of comparative data among drug classes, researchers have performed a retrospective study in ...


Cardiovascular autonomic diabetic neuropathy ( CAN ) is a serious complication of diabetes. No reliable data on the prevalence of cardiovascular autonomic neuropathy among patients with newly diagnose ...


Low levels of serum 25-hydroxyvitamin D [ 25(OH)D ] are commonly found in type 2 diabetes. Researchers have examined whether there is an association between circulating 25(OH)D concentrations and th ...


The aims of the study were to investigate weight loss and glycemic control parameters after different bariatric surgical procedures in type 2 diabetes ( T2D ) obese patients and identify patients' fac ...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes, age, obesity, and ethnicity. Hypertension is a major risk fact ...


Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy for type 2 diabetes mellitus that could provide robust glucose-loweri ...


The efficacy and safety of Lixisenatide ( Lyxumia ), a once-daily prandial glucagon-like peptide-1 ( GLP-1 ) receptor agonist, in older patients with type 2 diabetes mellitus ( T2DM ) insufficiently c ...


The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinol ...


Small cross-sectional studies have suggested that Metformin, a first-line oral hypoglycemic agent, may lower thyroid-stimulating hormone ( TSH ) levels. The objective of a study was to determine whe ...


The extent to which change in physical activity can modify the risk of cardiovascular disease in individuals at high cardiovascular risk is uncertain. Researchers have investigated whether baseline ...


Since protein ingestion is known to stimulate the secretion of glucagon-like peptide-1 ( GLP-1 ), researchers have hypothesised that enhancing GLP-1 secretion to harness its insulinotropic / beta cell ...


Diabetes mellitus is a leading cause of chronic kidney disease ( CKD ) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macr ...


An observational study has shown that patients with type 2 diabetes mellitus treated with a combination of Sitagliptin and Metformin initiated Insulin therapy at a slower rate during the period of obs ...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1 ) receptor agonists and basal insulins. In DURATION-3, ...


Although carbohydrate counting is the recommended dietary strategy for achieving glycaemic control in people with type 1 diabetes mellitus, the advice is based on narrative review and grading of the a ...


Previous studies have yielded conflicting results about the association between incretin therapies and acute pancreatitis. Researchers have compared the occurrence of acute pancreatitis in a populatio ...



Results from an observational study that has assessed the differences in time to initiation of Insulin use and the proportion of the population initiating Insulin among patients with type 2 diabetes t ...


The objective of a study was to evaluate the pharmacokinetics, efficacy and safety of Lixisenatide ( subcutaneous injection ) ( Lyxumia ) in elderly ( greater than or equal to 65 years old ) and very ...


Patients were twice as likely to have a diabetic foot ulcer heal within eight weeks when they were treated with a tissue repair drug versus a placebo, according to new research published in the Journa ...


Researchers have compared stepwise addition of bolus Insulin with a full basal-bolus regimen in patients with type 2 diabetes inadequately controlled on basal Insulin plus oral antidiabetic drugs. ...


Vitamin D is known as a major regulator of calcium levels and bone metabolism. Furthermore, it also influences the immune system. Previous studies have shown that patients with recently diagnosed type ...


The aim was to assess the efficacy and safety of Dapagliflozin ( Forxiga ) as add-on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 inhibitor w ...


Metformin ( Glucophage ) is the only first-line oral hypoglycaemic drug for type 2 diabetes recommended by international guidelines with proven efficacy, safety, and cost-effectiveness. However, littl ...


According to research published in Diabetologia, the journal of the European Association for the Study of Diabetes, people who have diabetes at the time they are diagnosed with cancer are more likely ...


New research published in Diabetologia, the journal of the European Association for the Study of Diabetes ( EASD ), has shown that diabetes mellitus in women is associated with an increased risk of st ...


Clinical trials have demonstrated that Metformin increases the efficiency of systemic therapy in cancer patients. Researchers examined whether the efficacy of conventional treatment of differentiat ...


The aim of the study was to investigate the long-term safety and efficacy of Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 inhibitor ( SGLT2 ); Sitagliptin ( Januvia ); and Metformin ( ...


Glucagon-like peptide-1 receptor agonists Exenatide ( Byetta ) and Liraglutide ( Victoza ) have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes.The effic ...


The cardiovascular safety and efficacy of many current antihyperglycemic agents, including Saxagliptin ( Onglyza ), a dipeptidyl peptidase 4 ( DPP-4 ) inhibitor, are unclear.Researchers have randomly ...


Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes, and revealed a possible molecular target for tr ...


Diabetes is a risk factor for dementia. It is unknown whether higher glucose levels increase the risk of dementia in people without diabetes mellitus.Researchers used 35,264 clinical measurements of g ...


Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence.The aim of the study ( INTERVAL ) was to assess the feasibility of ...


Studies have shown that, when implemented early in the course of type 2 diabetes mellitus, treatment with intensive Insulin therapy for 2-3 weeks can induce a glycaemic remission, wherein patients are ...


Effective reduction of albuminuria and blood pressure in patients with type 2 diabetes mellitus who have nephropathy is seldom achieved with available treatments. Researchers tested the effects of tre ...


The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new class of medications called sodium glu ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati